866-997-4948(US-Canada Toll Free)

BioMarker Strategies LLC - Product Pipeline Analysis, 2017 Update

Published By :

GlobalData

Published Date : Jun 2017

Category :

Industry Profile

No. of Pages : 29 Pages

Summary

BioMarker Strategies LLC (BioMarker Strategies) is a biotechnology company that develops tissue-based cancer diagnostic systems. The company offers cancer diagnostics system for predictive tests to targeted treatments for solid tumor malignancies. It also offers pathmap functional signaling profiles, which are a class of biomarker tests. BioMarker Strategies snappath is used for predictive tests to guide targeted drug development and treatment selection. The companys pathmap profiles provide predictive tests to guid targeted drug development, information on signal transduction networks, which include pathway activation and feedback loops that predicts patient response to targeted drug therapy. Its products are used in early clinical studies for assessing pharmacodynamic changes in the solid tumors. BioMarker Strategies is headquartered in Rockville, Maryland, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioMarker Strategies LLC
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
BioMarker Strategies LLC Company Overview 4
BioMarker Strategies LLC Company Snapshot 4
BioMarker Strategies LLC Pipeline Products and Ongoing Clinical Trials Overview 4
BioMarker Strategies LLC Pipeline Analysis Overview 7
BioMarker Strategies LLC - Key Facts 7
BioMarker Strategies LLC - Major Products and Services 8
BioMarker Strategies LLC Pipeline Products by Development Stage 9
BioMarker Strategies LLC Pipeline Products Overview 11
Ex Vivo Biomarker Test - Breast Cancer 11
Ex Vivo Biomarker Test - Breast Cancer Product Overview 11
Ex Vivo Biomarker Test - Colon Cancer 12
Ex Vivo Biomarker Test - Colon Cancer Product Overview 12
Ex Vivo Biomarker Test - Lung Cancer 13
Ex Vivo Biomarker Test - Lung Cancer Product Overview 13
Ex Vivo Biomarker Test - Melanoma 14
Ex Vivo Biomarker Test - Melanoma Product Overview 14
Ex Vivo Biomarker Test - Pancreatic Cancer 15
Ex Vivo Biomarker Test - Pancreatic Cancer Product Overview 15
Ex Vivo Biomarker Test - Solid Tumors 16
Ex Vivo Biomarker Test - Solid Tumors Product Overview 16
PathMAP 17
PathMAP Product Overview 17
PathMAP NSCLC 18
PathMAP NSCLC Product Overview 18
BioMarker Strategies LLC - Key Competitors 19
BioMarker Strategies LLC - Key Employees 20
BioMarker Strategies LLC - Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
BioMarker Strategies LLC, Recent Developments 22
Sep 19, 2016: BioMarker Strategies Awarded Phase I National Cancer Institute Contract to Develop Novel Predictive Test for Response to Immunotherapies for Patients with Non-Small Cell Lung Cancer 22
Jun 29, 2016: BioMarker Strategies Awarded Phase I/II Fast Track National Cancer Institute Grant to Develop Companion Diagnostic Test to Select Optimal Therapy for Patients with Non-Small Cell Lung Cancer 22
Jan 07, 2016: BioMarker Strategies Announces Issuance of Key Patents in the United States, Europe, Australia and Hong Kong 23
Jun 01, 2015: Dr. Samuel Broder, Former Director of the National Cancer Institute, Joins BioMarker Strategies as Chairman, Scientific Advisory Board 23
Sep 25, 2013: BioMarker Strategies Awarded $1.5 Million National Cancer Institute Contract to Develop Companion Diagnostic Test to Select Optimal Therapy for Melanoma Patients 24
Oct 03, 2012: BioMarker Strategies Appoints Jack Davis As Executive Chairman 24
May 27, 2011: BioMarker Strategies Appoints Glenn Miller To Board Of Directors As Chairman 24
Jan 03, 2011: BioMarker Strategies Appoints Three New Directors 25
Oct 07, 2009: NCI Grants Fast-Track SBIR Contract To BioMarker Strategies For Development Of SnapPath System 25
Jul 09, 2008: BioMarker Strategies Announces Executive Changes 25
Appendix 26
Methodology 26
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
BioMarker Strategies LLC Pipeline Products and Ongoing Clinical Trials Overview 4
BioMarker Strategies LLC Pipeline Products by Equipment Type 5
BioMarker Strategies LLC Pipeline Products by Indication 6
BioMarker Strategies LLC, Key Facts 7
BioMarker Strategies LLC, Major Products and Services 8
BioMarker Strategies LLC Number of Pipeline Products by Development Stage 9
BioMarker Strategies LLC Pipeline Products Summary by Development Stage 10
Ex Vivo Biomarker Test - Breast Cancer - Product Status 11
Ex Vivo Biomarker Test - Breast Cancer - Product Description 11
Ex Vivo Biomarker Test - Colon Cancer - Product Status 12
Ex Vivo Biomarker Test - Colon Cancer - Product Description 12
Ex Vivo Biomarker Test - Lung Cancer - Product Status 13
Ex Vivo Biomarker Test - Lung Cancer - Product Description 13
Ex Vivo Biomarker Test - Melanoma - Product Status 14
Ex Vivo Biomarker Test - Melanoma - Product Description 14
Ex Vivo Biomarker Test - Pancreatic Cancer - Product Status 15
Ex Vivo Biomarker Test - Pancreatic Cancer - Product Description 15
Ex Vivo Biomarker Test - Solid Tumors - Product Status 16
Ex Vivo Biomarker Test - Solid Tumors - Product Description 16
PathMAP - Product Status 17
PathMAP - Product Description 17
PathMAP NSCLC - Product Status 18
PathMAP NSCLC - Product Description 18
BioMarker Strategies LLC, Key Employees 20
Glossary 27

List of Figures
BioMarker Strategies LLC Pipeline Products by Equipment Type 5
BioMarker Strategies LLC Pipeline Products by Development Stage 9

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *